v
rumors of a possible merger between two drug giants: the American Pfizer could make its move to acquire the British GlaxoSmithKline by the end of the year, reports 'Pharma Times‘.
Market rumors about the potential deal are growing more insistent, and Deutsche Bank analyst Gregg Gilbert published a note titled 'Introducing PfizerKline', explaining that a deal would be "materially accretive" for both parties. As a baseline scenario, the analysts are assuming a purchase price of £1.924 per share, or about $146 billion in total.
But there are also those who doubt that this 'marriage' can be done: analyst Andrew Baum refutes the idea. "We doubt - he says - that GSK could be a viable acquisition target for Pfizer", also due to the probable opposition of the British government, which could be even higher than that made for AstraZeneca, when the US giant tried to acquire it last year " .
However, a survey conducted among 500 readers of the specialized site 'Biospace' highlighted how 63% believes Pfizer will make an offer for Gsk. 48% indicates the offering will be made in the third quarter of this year and 35% thinks it will be in excess of $120 billion.
Barbara Di Chiara – 25 May 2015 – PharmaKronos
Ed.: CEO of Pfizer is Ian C. Read, 60 years old, received during the fiscal year 2014 a total compensation of $ 23.283.048
CEO of Glaxosmithkline is Andrew Philip Witty, 49 years old, received during the fiscal year 2014 a total compensation of £ 3.891.000 [pounds]
